tiprankstipranks
Sage Therapeutics, Biogen complete NDA to FDA for zuranolone
The Fly

Sage Therapeutics, Biogen complete NDA to FDA for zuranolone

Sage Therapeutics (SAGE) and Biogen (BIIB) announced the completion of the rolling submission of a New Drug Application to the U.S. FDA for zuranolone in the treatment of major depressive disorder and postpartum depression. Zuranolone is an investigational drug being evaluated as a rapid-acting, once-daily, 14-day oral short course treatment in adults with MDD and PPD. The submission completes the NDA filing that was initiated earlier this year.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on SAGE:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles